Treating depression in Parkinson's disease patients: New research
News Apr 22, 2014
A group of scientists from the University of Kentucky College of Medicine and the Sanders-Brown Center on Aging has found interesting new information in a study on depression and neuropsychological function in Parkinson's disease (PD).
Published in the journal Psychiatry Research, the study, which assessed cognitive function in depressed and non-depressed patients with PD, found that the dopamine replacement therapy commonly used to treat motor symptoms of Parkinson's disease was associated with a decline in cognitive performance among depressed Parkinson patients.
In contrast, non-depressed Parkinson patients' cognitive function improved on dopamine replacement therapy.
The study also found that mood in depressed Parkinson's patients was actually worse while on dopaminergic medications.
"This was a surprise," said Lee Blonder, Ph.D., the study's principal investigator. "It is the opposite of our original hypothesis that both groups of PD patients would improve in cognitive performance on dopaminergic medications, and that mood in the depressed PD group would also improve."
A cohort of 28 patients with PD -- 18 nondepressed and 10 depressed -- were given a baseline series of tests to assess cognitive function and the incidence and severity of depression. They were then re-tested with and without their dopamine replacement therapy.
Results revealed a statistically signi?cant interaction between depression and medication status on three measures of verbal memory and a facial affect naming task. In all cases, depressed Parkinson's patients performed signi?cantly more poorly while on dopaminergic medication than while off. The opposite pattern emerged for the non-depressed Parkinson's group.
Depression is a common and serious co-morbidity in patients with Parkinson's; studies suggest that approximately 40 percent of PD patients suffer from depression.
Blonder cautions that these results are to some extent preliminary due to the small cohort of 28 participants. "Additional studies are required before these results should be used to alter treatment plans," Blonder says. But, "future research should ultimately focus on investigating treatment options for patients with Parkinson's and depression to maximize patient function without compromising their mental health."
Note: Material may have been edited for length and content. For further information, please contact the cited source.
Lee X. Blonder, John T. Slevin, Richard J. Kryscio, Catherine A. Martin, Anders H. Andersen, Charles D. Smith, Frederick A. Schmitt. Dopaminergic modulation of memory and affective processing in Parkinson depression. Psychiatry Research, Published Online July 8 2013. doi: 10.1016/j.psychres.2013.06.003
All in a Droplet: Atomic Resolution of ALS Protein ResolvedNews
Researchers have described atom-by-atom changes in a family of proteins linked to amyotrophic lateral sclerosis (ALS), a group of brain disorders known as frontotemporal dementia and degenerative diseases of muscle and bone.READ MORE
Pupil Size Couples to Cortical States to Protect Deep Sleep StabilityNews
Researchers have found that mice pupil size fluctuates during sleep. They also show that pupil size is a reliable indicator of sleep states.READ MORE
A Place to Think: Persistent neuronal activity in human prefrontal cortex links perception and actionNews
Neuroscientists have tracked the progress of a thought through the brain, showing clearly how the prefrontal cortex at the front of the brain coordinates activity to help us act in response to a perception.READ MORE